We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Biomarker Panel Improves Assessment of Pediatric Chronic Kidney Disease

By LabMedica International staff writers
Posted on 12 Jun 2025

Pediatric chronic kidney disease (CKD) is a serious condition that can advance to kidney failure, requiring dialysis or transplantation. More...

Given the high mortality rates associated with kidney failure in children, clinicians urgently need better tools to predict which patients are most at risk of disease progression. Now, researchers have identified a biomarker panel that significantly improves the ability to assess CKD progression in children, supporting better clinical monitoring and more precise enrollment in clinical trials.

The panel was developed by researchers at Yale School of Medicine (New Haven, CT, USA) who were involved in the Chronic Kidney Disease (CKD) Biomarkers Consortium, building on previous work to identify markers of kidney tubule health, injury, dysfunction, and inflammation. The latest study was conducted through the Chronic Kidney Disease in Children (CKiD) Cohort Study and involved over 500 children aged six months to sixteen years. To develop the panel, the researchers measured biomarkers in both plasma and urine samples and applied regression tree–based statistical modeling to determine the most informative predictors of disease progression. This modeling technique allowed them to identify a combination of markers that together offer more accurate prognostic insights than current standard measures alone.

The final biomarker panel included four key indicators: urine albumin/creatinine ratio, urine epidermal growth factor/creatinine ratio, plasma kidney injury molecule-1, and estimated glomerular filtration rate (eGFR). These biomarkers emerged as the most predictive for identifying children at the highest risk of CKD progression. In clinical practice, this panel offers substantial practical advantages. For children and their families, having a clearer understanding of disease progression risk allows for tailored management. Those at higher risk can adopt proactive preventative strategies, while those at lower risk may be able to reduce the frequency of medical visits, helping preserve critical childhood experiences and reducing unnecessary disruptions to daily life.

“While current clinical biomarkers only partially capture the variability of CKD progression, this research demonstrates that a combination of biomarkers which represent key pathways of kidney health can significantly improve risk prediction,” said Yale researcher Jason Greenberg, MD, MHS, who led the study. “This research could help physicians with clinical monitoring and treatment strategies for individual patients, potentially slowing disease progression and improving long-term outcomes.”


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.